The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN

The first-in-class inhibitor of ALK, c-MET and ROS1, crizotinib (Xalkori), has shown remarkable clinical efficacy in treatment of ALK-positive non-small cell lung cancer. However, in neuroblastoma, activating mutations in the ALK kinase domain are typically refractory to crizotinib treatment, highli...

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, J., Tucker, E. R., Wan, H., Chand, D., Danielson, L. S., Ruuth, K., El Wakil, A., Witek, B., Jamin, Y., Umapathy, G., Robinson, S. P., Johnson, T. W., Smeal, T., Martinsson, T., Chesler, L., Palmer, R. H., Hallberg, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Company of Biologists Ltd 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5047689/
https://www.ncbi.nlm.nih.gov/pubmed/27483357
http://dx.doi.org/10.1242/dmm.024448

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5047689/
https://www.ncbi.nlm.nih.gov/pubmed/27483357
http://dx.doi.org/10.1242/dmm.024448

Ejemplares similares